Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1B, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma

NCT03267940 is registered in ClinicalTrials.gov with Halozyme Therapeutics as lead sponsor.

NCT NCT03267940
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03267940 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1B, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
Lead sponsor
Halozyme Therapeutics
Phase
Phase 1
Overall status
Terminated
Start date
October 2, 2017
Completion date
November 11, 2019
Enrollment
85 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

cholangiocarcinoma non-resectable, cholangiocarcinoma, extrahepatic, cholangiocarcinoma, intrahepatic, gallbladder adenocarcinoma